FDA seeks more safety data on Byetta from Lilly, Amylin

12/23/2009 | Bloomberg

The FDA asked Eli Lilly and Co. and Amylin Pharmaceuticals to conduct more safety studies on Byetta in light of reports linking the diabetes drug to pancreatitis. The companies, which co-market the drug, said additional studies are under way and so far have shown no heightened risk of pancreatitis in patients using Byetta.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA